Afya Limited reported fourth‑quarter and full‑year 2025 results on March 13 2026, delivering earnings per share of $0.42 versus the consensus estimate of $0.37. Revenue for the quarter was $169.13 million, falling short of the $174.74‑$175.15 million consensus estimate, but the company’s adjusted earnings growth of 13.9% YoY reflected stronger profitability and disciplined cost management.
The earnings beat was driven by a combination of tighter operating leverage and a favorable mix of high‑margin segments. Adjusted EBITDA margin for the quarter rose to 42.6% from 42.0% a year earlier, and the full‑year margin climbed to 45.4%, up 130 basis points. These margin gains offset the revenue shortfall and enabled the company to exceed earnings expectations.
Revenue missed estimates largely because of foreign‑exchange headwinds that reduced the U.S. dollar translation of Brazilian‑real‑denominated sales. Despite the miss, revenue grew 7.5% YoY to $169 million, and the company’s core undergraduate and continuing‑education segments continued to expand, while the medical‑practice‑solutions segment faced a modest decline in volume.
Management reiterated its 2026 revenue guidance of R$3,950 million to R$4,100 million, which converts to roughly $790 million to $820 million at a 5 BRL‑to‑1 USD rate. The guidance signals confidence in sustaining margin expansion through operational discipline, even as the company plans increased strategic investments in technology and physician‑engagement platforms.
CFO Luis André Blanco noted that fourth‑quarter revenue of BRL 913 million represented an 8% YoY increase, and full‑year revenue of BRL 3.697 billion grew 12% year‑over‑year. He added that adjusted EBITDA rose 6% to BRL 389 million, with a margin of 42.6%, and that full‑year adjusted EBITDA reached BRL 1.680 billion, a 15% increase with a 45.4% margin.
The results underscore Afya’s ability to generate strong earnings even amid revenue volatility, but the recurring revenue misses and the need for higher capital spending in 2026 highlight the company’s focus on long‑term growth and market leadership in Brazil’s regulated medical‑education sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.